STUDY OF EFFECT OF GLYCEMIC CONTROL IN CKD DIABETIC PATIENTS AND THEIR RELATION TO HYPOGLYCEMIA C-PEPTIDE AND ISLET ANTIBODIES

	STUDY OF EFFECT OF GLYCEMIC CONTROL IN CKD DIABETIC PATIENTS AND THEIR RELATION TO HYPOGLYCEMIA C-PEPTIDE AND ISLET ANTIBODIES
Article 1, Volume 6, Issue 1, January 2024, Page 30-31
Document Type: Preliminary preprint short reports of original research
DOI: 10.21608/alexpo.2024.265209.1780
View on SCiNiTO
Authors
Magdy Helmi Megalla¹; Mona Wagdy Helmy²; Mohamed Said Abd Elsalam¹; Mohamed Said Koheya ³
¹Department of Internal Medicine, Faculty of Medicine, Alexandria University
²Department of Clinical and Chemical Pathology, Faculty of Medicine Alexandria University
³Department of Internal Medicine , Faculty of Medicine , Alexandria University
Abstract
Diabetes mellitus is a major public health issue with an increasing prevalence worldwide. In Egypt, DM is the leading cause of chronic kidney failure. Classification: type I DM, type II DM, Gestational DM, MoDY, LADA. Complication: Diabetic nephropathy is significant cause of morbidity and mortality in DM patients with progression to ESRD. Figure (1): NICE/KDIGO classification of CKD using eGFR and ACR categories. Hypoglycemic Hypoglycemic is an essential and frequent adverse effect of glycemic control, as it causes significant morbidity and mortality. A plasma glucose concentration of
Keywords
CKD; HYPOGLYCEMIA; C-PEPTIDE
Supplementary Files 1780 14 (5).pdf 1780 14 (5).pdf 1780 14 (5).pdf

Statistics Article View: 62